Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods Under Section 41

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods available in Australia are of an acceptable quality, safety, and efficacy. The Act provides the legislative framework for regulating the supply, manufacture, and advertising of therapeutic goods within Australia. It was introduced to address the problem of ensuring public health protection by regulating therapeutic goods, including medicines, medical devices, and blood products, through a licensing system that mandates quality and safety standards. The Therapeutic Goods Administration, a division of the Department of Health, administers this Act. The policy objective is to safeguard public health by controlling the quality, safety, and efficacy of therapeutic goods through rigorous regulatory processes. This Act empowers the Secretary of the Department of Health to take action, such as suspending a manufacturer's licence, to maintain these standards and protect the health of the Australian public.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, and advertising of therapeutic goods in Australia. This includes companies, corporations, and individuals who engage in activities related to the production, distribution, and sale of therapeutic goods, which encompass a wide range of products including medicines, medical devices, blood, and tissues. The act applies across the Commonwealth of Australia and is enforced by the Therapeutic Goods Administration (TGA). The suspension of a manufacturer’s licence, as detailed in the gazette, is a mechanism by which the TGA can temporarily restrict the operations of a manufacturer found to be in non-compliance with regulatory standards. The specified suspension periods for Cyclopet Pty Ltd, Veolia Environmental Services (Australia) Pty Ltd, and Royal Adelaide Hospital Radiopharmacy are at the request of the manufacturers themselves, indicating a voluntary compliance measure. The act provides for various exclusions and exemptions through subordinate legislation, which may include certain classes of therapeutic goods, research activities, and small-scale operations that do not pose significant risks to public health.

Key Provisions

Section 41(1)(d) of the Therapeutic Goods Act 1989 empowers the Secretary of the Department of Health to suspend a licence to manufacture therapeutic goods. In this instance, the licences of three entities have been suspended: Cyclopet Pty Ltd, Veolia Environmental Services (Australia) Pty Ltd, and Royal Adelaide Hospital Radiopharmacy. The suspension of these licences was requested by the manufacturers themselves, which is a notable aspect of these cases. The suspensions are for specific periods, with Cyclopet Pty Ltd’s licence suspended from 20 August 2019 to 19 August 2020, Veolia Environmental Services (Australia) Pty Ltd’s licence from 28 June 2019 to 28 June 2020, and Royal Adelaide Hospital Radiopharmacy’s licence from 28 June 2019 to 1 July 2020. The obligations and requirements imposed by the Therapeutic Goods Act 1989 on the entities named include maintaining the quality and safety of therapeutic goods, ensuring compliance with all relevant regulations, and reporting any issues that could affect the quality or safety of the products. For the period of suspension, these entities must cease manufacturing activities, which may involve halting production, conducting necessary reviews or audits, and ensuring that any ongoing manufacturing is transferred to compliant facilities or other licensed entities. They must also refrain from marketing or distributing any therapeutic goods produced during the suspension period unless they have received explicit approval from the Therapeutic Goods Administration (TGA). Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in significant legal consequences. Under section 95 of the Act, offences related to the unauthorised manufacture of therapeutic goods can attract penalties of up to 120,000 penalty units for individuals and 600,000 penalty units for bodies corporate. Additionally, section 96A provides for the potential criminal prosecution of officers of a body corporate who are responsible for the contravention. Civil penalties, including fines and injunctions, may also be imposed under sections 83 and 84 of the Act. It is crucial for the suspended entities to adhere strictly to the terms of their suspension to avoid these serious legal ramifications.